Levin Calls Takeda/Shire Merger ‘Inspired,’ Says Entire Value Chain Must Address Pricing Issue
Executive Summary
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.